gene editing platform

LONDON: Abcam Plc has announced the asset purchase of the gene editing platform and oncology product portfolio of Applied StemCell, Inc. (ASC) for life science research and diagnostic markets.  As a global life sciences company, Abcam identifies, develops, and distributes high-quality biological reagents and tools that are crucial to research, drug discovery and diagnostics. Over…